Drawing for TOLERO PHARMACEUTICALS

USPTO serial 86418815

TOLERO PHARMACEUTICALS

Reviewed by CopyMark Law Group

Reg. 4751574Status 710
Filing date
Status date
Registration date
Jun 9, 2015
Examiner
BUSH, KAREN K
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with TOLERO PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Howard N. Aronson

Howard N. Aronson Lackenbach Siegel LLP1 Chase RdLackenbach Siegel BuildingScarsdale, NY 10583-4156

Goods and services

ClassDescriptionStatusFirst use
042Bacteriological research; Bacteriological research and testing; Biochemical research and development; Biological research; Biomedical research services; Biotechnology research; Chemical analysis; Chemical engineering; Chemical laboratories; Chemical research; Chemical, biochemical, biological and bacteriological research and analysis; Chemist services; Conducting clinical trials for others; Conducting early evaluations in the field of new pharmaceuticals; Consultancy pertaining to pharmacology; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of new technology for others in the field of pharmacology; Development of pharmaceutical preparations and medicines; Drug discovery services; Executing of chemical analyses; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genetic testing of laboratory animals for research purposes; Laboratory analysis in the field of pharmacology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research in the field of pharmacology; Medical and scientific research information in the field of pharmacology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services in the field of cancer; Performance of chemical analyses; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of chemistry; Research on the subject of pharmaceuticals; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research for medical purposes in the area of cancerous diseases; Scientific research in the field of genetics and genetic engineering; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Working on and evaluation of chemical analyses; Working on and evaluation of chemical synthesesSECTION 8 - CANCELLEDAug 1, 2011

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 10, 2021C8..CANCELLED SEC. 8 (6-YR)—
Jun 9, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Feb 9, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 9, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 13, 2017ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jun 9, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 24, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 24, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 4, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 14, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 13, 2015ALIEASSIGNED TO LIE—
Jan 27, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 27, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Jan 27, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 27, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 27, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 27, 2015DOCKASSIGNED TO EXAMINER—
Oct 15, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 11, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance